Biotechgate Global Database ›
News in the Life Sciences Industry | |
| Results 81 - 100 out of 110 displayed. | |
| « 1 2 3 4 5 6 » | |
Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody) |
SONGDO, South Korea, April 22, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018. As a result, ImmuneOncia will begin Phase... Read more ›› |
| By: PR Newswire Association LLC. - 23 Apr 2020 |
| Related companies: Samsung Biologics Co., Ltd. | ImmuneOncia Therapeutics Inc. |
Novo Nordisk A/S – Share repurchase programme |
| Read more ›› |
| By: GlobenewsWire - 20 Apr 2020 |
OliX Pharmaceuticals Expands Scientific Advisory Board with Addition of Leading Liver Experts |
| Read more ›› |
| By: GlobenewsWire - 17 Apr 2020 |
| Related companies: OliX Pharmaceuticals, Inc |
CirrusDx Laboratory Receives Emergency Use Authorization from FDA for COVID-19 Testing |
ROCKVILLE, Md., April 16, 2020 /PRNewswire/ -- Cirrus Dx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, received Emergency Use Authorization (EUA) from the US Food & Drug Administration (FDA) to perform SARS-COVID-19 testing. Read more ›› |
| By: PR Newswire Association LLC. - 16 Apr 2020 |
| Related companies: Seegene, Inc. | Seegene Technologies Inc. | Seegene Canada Inc. | Seegene USA |
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis |
SEONGNAM, South Korea, April 9, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced the interim data from the first cohort in the phase 2a study of BBT-401, an experimental drug for the treatment of ulcerative... Read more ›› |
| By: PR Newswire Association LLC. - 09 Apr 2020 |
Novo Nordisk A/S – Share repurchase programme |
| Read more ›› |
| By: GlobenewsWire - 06 Apr 2020 |
Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection |
| Read more ›› |
| By: GlobenewsWire - 06 Apr 2020 |
Yuyu Pharma appoints Robert Wonsang Yu as incoming President and CEO |
SEOUL, South Korea, April 5, 2020 /PRNewswire/ -- Yuyu Pharma (KRX: 000220), a global pharmaceutical company based in Korea, is pleased to announce the appointment of Mr. Robert Wonsang Yu as President and Chief Executive Officer effective April 6, 2020. Read more ›› |
| By: PR Newswire Association LLC. - 06 Apr 2020 |
| Related companies: Yuyu Pharma, Inc. |
Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment |
SONGDO, South Korea, April 5, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders. Under... Read more ›› |
| By: PR Newswire Association LLC. - 06 Apr 2020 |
| Related companies: Samsung Biologics Co., Ltd. |
Yuyu Pharma Appoints Robert Wonsang Yu as President Designate |
SEOUL, South Korea, April 6, 2020 /PRNewswire/ -- Yuyu Pharma (KRX: 000220), a global pharmaceutical company based in Korea, is pleased to announce the appointment of Mr. Robert Wonsang Yu as President and Chief Executive Officer effective April 6, 2020. Read more ›› |
| By: PR Newswire Association LLC. - 06 Apr 2020 |
| Related companies: Yuyu Pharma, Inc. |
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU |
| Read more ›› |
| By: GlobenewsWire - 04 Apr 2020 |
Yuyu Pharma introduces new advanced ERP management system |
SEOUL, South Korea, March 31, 2020 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX 000220) introduced a new Enterprise Resource Planning (ERP) system to identify real-time management conditions and enhance system management for more efficient decision-making. Read more ›› |
| By: PR Newswire Association LLC. - 31 Mar 2020 |
| Related companies: Yuyu Pharma, Inc. |
GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma |
TOKYO, March 30, 2020 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of 3.29 billion yen (US$30 million*) to invest in 11 partnerships to develop new lifesaving drugs, vaccines and diagnostics for malaria, tuberculosis, Chagas disease, leishmaniasis,... Read more ›› |
| By: PR Newswire Association LLC. - 31 Mar 2020 |
OliX Pharmaceuticals and AM Chemicals Announce Exclusive Licensing and Supply Agreement for GalNAc-Conjugation Technology for Liver Targeting |
| Read more ›› |
| By: GlobenewsWire - 30 Mar 2020 |
| Related companies: OliX Pharmaceuticals, Inc |
Novo Nordisk A/S - Share repurchase programme |
| Read more ›› |
| By: GlobenewsWire - 30 Mar 2020 |
Resolutions from the Annual General Meeting of Novo Nordisk A/S |
| Read more ›› |
| By: GlobenewsWire - 26 Mar 2020 |
Novo Nordisk A/S - Articles of Association |
| Read more ›› |
| By: GlobenewsWire - 26 Mar 2020 |
Novo Nordisk A/S – Share repurchase programme |
| Read more ›› |
| By: GlobenewsWire - 23 Mar 2020 |
OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs |
| Read more ›› |
| By: GlobenewsWire - 20 Mar 2020 |
| Related companies: OliX Pharmaceuticals, Inc |
Novo Nordisk A/S – Share repurchase programme |
| Read more ›› |
| By: GlobenewsWire - 16 Mar 2020 |
| « 1 2 3 4 5 6 » |
Partners
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation
